Browser storage is unavailable. Keep this page open and export your collection before leaving.
Perlara
Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by sel
Overview
Perlara 1.0 (Feb 2014 - Feb 2019) launched early R&D joint ventures called PerlQuests with highly motivated rare disease families, companies or impact investors. We screened gene-edited patient avatars for repurposable drugs in order to build a predictive R&D engine called ArkBase. We planned to monetize programs based on ArkBase predictions by selectively spinning out asset-centric clinical development NewCos.
Perlara 1.5 (March 2019 - April 2020) was the transition to a one-person virtual clinical development company and when the epalrestat and aripiprazole repurposing trials were launched at Mayo Clinic for the treatment of PMM2-CDG and NGLY1-CDDG, respectively.
Perlara 2.0 (May 2020 --> The first decentralized and distributed biotech
Founders & team
Previously Perlstein Lab PBC
No directly sourced team information is available yet.
Founded 2014 · Source
News & product activity
Sources & observations
Maturity: Not assessed · 2 of 6 areas documented
Source-based assessment · automated evidence rules
The retained text does not establish product availability or customer use.
Maturity is an evidence-based assessment, not a success rating. It may understate the current stage where evidence is limited. Coverage records documented areas, not a complete or independently audited company history.
- Product overviewSource description Checked 2026-11-08
- Product visualsNot documented
- Founders & originsNot documented
- Business model & pricingNot documented
- Funding & ownershipNot documented
- Dated milestonesDated source activity: 2016 Q1 (quarter only)





